Randomized Comparative Study of HCC with MPVTT Treated by Portal Vein Stent and TACE Combined with or Without Endovascular Implantation of Iodine-125 (125I) Seeds Strand

吴林霖,罗剑钧,颜志平,方主亭,张雯,张学彬,王建华,王小林
DOI: https://doi.org/10.3969/j.issn.1672-8467.2013.03.020
2013-01-01
Abstract:Objective To randomized block design and compare the efficacy of hepatocellular carcinoma(HCC)with main portal vein tumor thrombus(MPVTT)treated by portal vein stent and transcatneter arterial chemoembolization(TACE)combined with or without endovascular implantation of Iodine-125(125I)seeds strand.Methods Sixty patients with HCC complicated by MPVTT who received portal vein stent and TACE combined with(group A,n=30)or without(group B,n=30) endovascular implantation of 125I seeds strand in our hospital during Feb.2009and Apr.2011 were analyzed retrospectively.Overall survival,stent patency and procedure-related adverse event were compared between the two groups.Results Technical success rate was 100%for placement of 125I seeds strand and stent in the obstructed main portal vein.No serious procedure-related adverse events occurred.Median survival time of group A and B were 335days and 142days,respectively(P=0.002,HR= 2.683);Median stent patency period of group A and B were 340days and 190days,respectively(P=0.038,HR=2.252).Conclusions Portal vein stent and TACE combined with endovascular implantation of 125I seeds strand could improve the survival time,stent patency period of patients with HCC complicated by MPVTT and improve their quality of life effectively.It is a new approach to treat HCC with MPVTT.
What problem does this paper attempt to address?